Assorted news from the last two weeks:
Adolescents and young adult cancer survivors are more likely to have psychological distress and additional annual medical expenses than adults with no history of cancer, according to a study published in Cancer. The FDA has granted both Rare Pediatric Disease Designation and Orphan Drug Designation Lantern Pharma’s drug candidate LP-184 for the treatment of pediatric patients with ATRT. Two anti-cancer antibodies have a much stronger effect against pediatric nerve-cell and bone cancers in mice than either one alone, researchers have discovered. The Spanish perspective: The future of pediatric oncology lies in precision medicine. An answer to the question of why Ondansetron, a 5-HT3 receptor agonist that is widely used to manage chemotherapy-induced nausea and vomiting (CINV), seems to work better for some pediatric patients with cancer who experience CINV but not others. The COVID-19 pandemic is having a profound impact on pediatric oncology health care providers (HCPs), according to a study published online Jan. 24 in Cancer.
Upcoming Webinars and Online Opportunities:
- Juanita Prada (Survivor and Advocate)
- Pat Lacey (Beat Childhood Cancer)
- Stan Robbins (Advocate)
